MEI Pharma, Inc. Stock price
Is MEI Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.
Key metrics
MEI Pharma, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a MEI Pharma, Inc. forecast:
Analyst Opinions
6 Analysts have issued a MEI Pharma, Inc. forecast:
Don't miss a Thing! We will send you all news about MEI Pharma, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Mr. File |
| Employees | 28 |
| Founded | 2000 |
| Website | www.meipharma.com |


